SWOG clinical trial number
SWOG-9458

Evaluation of Ki-67, p53 and Angiogenesis in Patients Registered to SWOG-8710, Ancillary

Closed
Phase
Accrual
58%
Published
Abbreviated Title
Ancillary
Activated
11/15/1995
Closed
11/01/1998

Research committees

Genitourinary Cancer

Publication Information Expand/Collapse

2006

Evaluation of Ki67, p53 and angiogenesis in patients enrolled in a randomized study of neoadjuvant chemotherapy with or without cystectomy: a Southwest Oncology Group study

HB Grossman;CM Tangen;C Cordon-Cardo;R Cote;FM Waldman;RW De Vere White;AB Karnad;M Glode;ED Crawford Oncology Reports 16:807-810

2002

SWOG 9458: evaluation of Ki-67, p53 and angiogenesis in patients registered to SWOG 8710

HB Grossman;C Cordon-Cardo;R Cote;FM Waldman;C Tangen;ED Crawford International Journal of Cancer Suppl.13:114 (#O140)

Other Clinical Trials

SWOG Clinical Trial Number
S2419

Phase II/III Double Blinded Trial of Immune-Based Therapy with a Live Biotherapeutic MO-03, or Placebo for Frontline Therapy of Advanced Clear Cell Renal Cell Carcinoma (BioFront Trial)
Research Committee(s)
Genitourinary Cancer
Activated
04/22/2026
Accrual
0%
Open
Phase
SWOG Clinical Trial Number
S2427

Single Arm Phase II Study of Bladder Preservation with Immunoradiotherapy after a Clinically Meaningful Response to Neoadjuvant Therapy in Patients with Muscle Invasive Bladder Cancer (BRIGHT)
Research Committee(s)
Genitourinary Cancer
Activated
09/04/2025
Accrual
10%
Open
Phase
SWOG Clinical Trial Number
CCTG-PR26

A Randomized Phase III Clinical Trial for the Addition of Docetaxel to Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response (TRIPLE-SWITCH)
Research Committee(s)
Genitourinary Cancer
Activated
01/30/2025
Open
Phase